Zacks Small Cap Research – CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more
